Non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) is a buildup of excessive fat in the liver that can lead to liver damage resembling the damage caused by alcohol abuse, but that occurs in people who do not drink heavily. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. The liver normally contains some fat; an individual is considered to have a fatty liver (hepatic steatosis) if the liver contains more than 5 to 10 percent fat.

The fat deposits in the liver associated with NAFLD usually cause no symptoms, although they may cause increased levels of liver enzymes that are detected in routine blood tests. Some affected individuals have abdominal pain or fatigue. During a physical examination, the liver may be found to be slightly enlarged.

Between 7 and 30 percent of people with NAFLD develop inflammation of the liver (non-alcoholic steatohepatitis, also known as NASH), leading to liver damage. Minor damage to the liver can be repaired by the body. However, severe or long-term damage can lead to the replacement of normal liver tissue with scar tissue (fibrosis), resulting in irreversible liver disease (cirrhosis) that causes the liver to stop working properly. Signs and symptoms of cirrhosis, which get worse as fibrosis affects more of the liver, include fatigue, weakness, loss of appetite, weight loss, nausea, swelling (edema), and yellowing of the skin and whites of the eyes (jaundice). Scarring in the vein that carries blood into the liver from the other digestive organs (the portal vein) can lead to increased pressure in that blood vessel (portal hypertension), resulting in swollen blood vessels (varices) within the digestive system. Rupture of these varices can cause life-threatening bleeding.

NAFLD and NASH are thought to account for many cases of cirrhosis that have no obvious underlying cause (cryptogenic cirrhosis); at least one-third of people with NASH eventually develop cirrhosis. People with NAFLD, NASH, and cirrhosis are also at increased risk of developing liver cancer (hepatocellular cancer).

NAFLD is most common in middle-aged or older people, although younger people, including children, are also affected. It is often considered as part of a group of conditions known collectively as the metabolic syndrome; in addition to NAFLD, the metabolic syndrome includes obesity, type 2 diabetes or pre-diabetes (insulin resistance), high levels of fats (lipids) such as cholesterol and triglycerides in the blood, and high blood pressure (hypertension). However, a person with NAFLD may not have all or any of the other conditions that make up the metabolic syndrome, and individuals with some or all of those conditions may not have NAFLD.
Frequency

NAFLD is a very common disorder, occurring in about 25 percent of the global population. Its prevalence is increasing along with the rising prevalence of obesity in industrialized societies, and it is now the most common chronic liver disorder in Western countries, including the United States. NAFLD is more prevalent in individuals of Hispanic, Native American, or Asian ancestry than in individuals of European or African ancestry.

Genetic Changes

The specific causes of NAFLD are unclear. Genetic variations and environmental factors contribute to the development of this complex disorder.

When fat from the diet exceeds the body's requirements and ability to break it down and eliminate it, some of the fat is stored in the liver. Researchers suggest that overconsumption of certain specific nutrients, such as iron, cholesterol, and refined sugars used in processed foods, may increase the likelihood of developing NAFLD.

It is unclear what causes NASH and cirrhosis to develop in some people with NAFLD. Researchers are studying several possible mechanisms. These include inflammation caused by an immune system reaction to the excess fatty tissue in the liver; toxic inflammatory chemicals (cytokines) released by the liver cells or fat cells; self-destruction (apoptosis) of liver cells; and the effect of unstable molecules called free radicals (oxidative stress). The effects of different populations of microorganisms in the intestines (gut microbiota) on the breakdown and absorption of nutrients are also an active area of research.

Studies have identified many genetic changes that may be associated with the development of NAFLD and NASH. Among these is a particular variation in the PNPLA3 gene. This gene provides instructions for making a protein called adiponutrin, which is found in fat cells (adipocytes) and liver cells (hepatocytes). The function of this protein is not well understood, but it is thought to help regulate the production and breakdown of fats (lipogenesis and lipolysis) and the development of adipocytes. Studies indicate that the activity (expression) of the PNPLA3 gene decreases during periods without food (fasting) and increases after eating, suggesting that the amount of adiponutrin protein produced is regulated as needed to help process and store fats in the diet. The PNPLA3 gene variation associated with NAFLD is thought to lead to increased production and decreased breakdown of fats in the liver. Research is ongoing to determine how this and other genetic changes contribute to the development of NAFLD and its complications.

Inheritance Pattern

An increased risk of developing NAFLD can be passed through generations in families, but the inheritance pattern is unknown. Variations in several genes as well as lifestyle and environmental factors contribute to the risk of developing this complex disorder.
Other Names for This Condition

- fatty liver
- NAFLD
- NASH
- non-alcoholic steatohepatitis
- nonalcoholic fatty liver disease
- nonalcoholic steatohepatitis
- steatosis

Diagnosis & Management

Genetic Testing

• Genetic Testing Registry: Fatty liver disease, nonalcoholic 1

• Genetic Testing Registry: Fatty liver disease, nonalcoholic 2

Other Diagnosis and Management Resources

• MedlinePlus Encyclopedia: Liver Biopsy
  https://medlineplus.gov/ency/article/003895.htm

• MedlinePlus Encyclopedia: Liver Function Tests
  https://medlineplus.gov/ency/article/003436.htm

General Information from MedlinePlus

• Diagnostic Tests
  https://medlineplus.gov/diagnostictests.html

• Drug Therapy
  https://medlineplus.gov/drugtherapy.html

• Genetic Counseling
  https://medlineplus.gov/geneticcounseling.html

• Palliative Care
  https://medlineplus.gov/palliativecare.html

• Surgery and Rehabilitation
  https://medlineplus.gov/surgeryandrehabilitation.html
Additional Information & Resources

**MedlinePlus**
- Encyclopedia: Cirrhosis
  https://medlineplus.gov/ency/article/000255.htm
- Encyclopedia: Fatty liver -- Nonalcoholic
  https://medlineplus.gov/ency/article/007657.htm
- Encyclopedia: Liver Biopsy
  https://medlineplus.gov/ency/article/003895.htm
- Encyclopedia: Liver Function Tests
  https://medlineplus.gov/ency/article/003436.htm
- Health Topic: Fatty Liver Disease
  https://medlineplus.gov/fattyliverdisease.html
- Health Topic: Liver Cancer
  https://medlineplus.gov/livercancer.html

**Genetic and Rare Diseases Information Center**
- Nonalcoholic steatohepatitis
  https://rarediseases.info.nih.gov/diseases/6430/nonalcoholic-steatohepatitis

**Additional NIH Resources**
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Fatty Liver Disease
  https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash

**Educational Resources**
- American College of Gastroenterology
  http://patients.gi.org/topics/fatty-liver-disease-nafld/
- Disease InfoSearch: Non-alcoholic steatohepatitis (NASH)
  http://www.diseaseinfosearch.org/Non-alcoholic+steatohepatitis+(NASH)/5243
- MalaCards: nonalcoholic steatohepatitis
  http://www.malacards.org/card/nonalcoholic_steatohepatitis
- Merck Manual Consumer Version: Fatty Liver
- Orphanet: NON RARE IN EUROPE: Non-alcoholic fatty liver disease
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=33271
- University of Michigan: Searching for the Skinny on Fatty Liver Disease
  https://labblog.uofmhealth.org/lab-report/searching-for-skinny-on-fatty-liver-disease
Patient Support and Advocacy Resources

- American Liver Foundation
  https://liverfoundation.org/for-patients/about-the-liver/diseases-of-the-liver/non-alcoholic-fatty-liver-disease/
- Canadian Liver Foundation
  https://www.liver.ca/patients-caregivers/liver-diseases/fatty-liver-disease/

ClinicalTrials.gov

- ClinicalTrials.gov
  https://clinicaltrials.gov/ct2/results?cond=%22nonalcoholic+fatty+liver+disease%22+OR+%22Non-alcoholic+Fatty+Liver+Disease%22

Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28Non-alcoholic+Fatty+Liver+Disease%5BMAJR%5D%29+OR+%28nonalcoholic+fatty+liver+disease%5BTI%5D%29+AND+review%5Bpt%5D+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+720+days%22%5Bdp%5D

OMIM

- FATTY LIVER DISEASE, NONALCOHOLIC, SUSCEPTIBILITY TO, 1
  http://omim.org/entry/613282
- FATTY LIVER DISEASE, NONALCOHOLIC, SUSCEPTIBILITY TO, 2
  http://omim.org/entry/613387

MedGen

- Non-alcoholic fatty liver

Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27657051
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037841/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25624712
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299331/
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24222941 
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819533/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27350942 
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913080/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26676813 
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941959/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24785259

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24222094

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26850495 
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844071/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27547017 
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970479/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27247565 
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876215/


Reviewed: November 2016
Published: July 24, 2018

page 6
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services